BENGALURU, India & BRIDGEWATER, New Jersey, United States, April 7, 2026
Biocon Limited announced the U.S. commercial launch of Bosaya™ and Aukelso™ (denosumab-kyqq), two FDA-approved biosimilars with interchangeable designation, marking a major milestone in expanding affordable biologic treatment options for osteoporosis and oncology-related bone conditions. The launch strengthens Biocon’s position in the global biosimilars market and enhances access to high-quality, cost-effective therapies across the United States.
U.S. Launch Expands Access to Critical Bone Health Therapies
The introduction of Bosaya™ (biosimilar to Prolia®) and Aukelso™ (biosimilar to Xgeva®) provides physicians and patients with widely accessible denosumab-based therapies, now available nationwide through specialty pharmacies and healthcare providers. Both products received U.S. FDA approval in September 2025, along with interchangeable designation, enabling pharmacy-level substitution in accordance with state regulations.
Denosumab is a monoclonal antibody targeting RANK ligand (RANKL), a key regulator of bone resorption. By inhibiting RANKL, these therapies help reduce bone breakdown, increase bone density, and lower fracture risk, making them essential in the management of osteoporosis and cancer-related skeletal complications.
The U.S. market represents a significant opportunity, with approximately 10 million adults affected by osteoporosis and more than 330,000 patients annually experiencing bone metastases, underscoring the urgent need for accessible and effective treatment options.
Advertisement
Biosimilars Drive Cost Efficiency and Healthcare Sustainability
The launch of Bosaya™ and Aukelso™ highlights the growing importance of biosimilars in improving healthcare affordability and system sustainability. With denosumab therapies generating approximately $5 billion in U.S. sales annually, the introduction of biosimilars is expected to increase market competition, reduce treatment costs, and expand patient access.
Biosimilars are developed to meet stringent regulatory standards for quality, safety, and efficacy, ensuring comparable performance to reference biologics while offering more cost-effective alternatives. The interchangeable designation further enhances their adoption by enabling automatic substitution at the pharmacy level, simplifying access for patients and healthcare providers.
Biocon’s integrated approach, combining research, manufacturing, and commercialization, supports the reliable supply of biosimilars and reinforces its role as a global leader in biologics development.
Strengthening Oncology and Immunology Portfolio
The launch of these denosumab biosimilars represents a strategic expansion of Biocon’s oncology and immunology portfolio, addressing diseases with high unmet medical need. In addition to osteoporosis, denosumab is widely used in the treatment of bone metastases associated with advanced cancers, as well as giant cell tumor of bone, a rare but debilitating condition.
By expanding its biosimilars portfolio, Biocon aims to deliver life-changing therapies at scale, leveraging its global infrastructure and innovation-driven pipeline. The company currently operates in over 120 countries, supported by robust manufacturing capabilities and ongoing R&D investments, positioning it to meet the growing demand for biologic therapies worldwide.
The availability of Bosaya™ and Aukelso™ in prefilled syringe and vial formats also enhances treatment convenience and flexibility, improving patient adherence and clinical outcomes.
The U.S. commercial launch of Bosaya™ and Aukelso™ marks a significant advancement in biosimilar adoption, providing affordable, high-quality treatment options for osteoporosis and cancer-related bone diseases. With strong regulatory backing, clinical relevance, and market demand, Biocon is well-positioned to drive innovation, accessibility, and sustainability in the biopharmaceutical industry.
As the healthcare landscape continues to evolve, biosimilars will play an increasingly important role in reducing costs, improving patient access, and supporting global health systems, reinforcing their value in modern pharmaceutical development and commercialization.
Source: biocon biologics press release
